Obesity drug sibutramine (Meridia): Hypertension and cardiac arrhythmias

CMAJ. Canadian Medical Association Journal

Volumn 166, Issue 10, 2002, Pages 1307-1308

  Wooltorton, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DEXFENFLURAMINE; ECTIVA; FENFLURAMINE; REDUXADE; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONSTIPATION; DOPAMINE UPTAKE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG FATALITY; DRUG MARKETING; GALLSTONE; GLAUCOMA; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INSOMNIA; INTRAOCULAR HEMORRHAGE; MANIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK BENEFIT ANALYSIS; SATIETY; SEIZURE; SHORT SURVEY; STROKE; TACHYCARDIA; THORAX PAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0036098099     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (12)

1. Abbott says no link between deaths, obesity drug
2. Sibutramine and energy balance
3. Meridia (sibutramine HCl monohydrate, anorexiant-antiobesity)
4. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity
5. Long-term weight loss with sibutramine: A randomized controlled trial
6. Effect of sibutramine on weight maintenance after weight loss: A randomised trial
7. Drug therapy: Obesity
8. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
9. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebo-controlled, multicenter trial
10. Absence of cardiac valve dysfunction in obese patients treated with sibutramine